Skip to main content

Advertisement

SpringerLink
Log in

Molecular pathogenesis and current pathology of pulmonary hypertension

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Following its initial description over a century ago, pulmonary arterial hypertension (PAH) continues to challenge researchers committed to understanding its pathobiology and finding a cure. The last two decades have seen major developments in our understanding of the genetics and molecular basis of PAH that drive cells within the pulmonary vascular wall to produce obstructive vascular lesions; presently, the field of PAH research has taken numerous approaches to dissect the complex amalgam of genetic, molecular and inflammatory pathways that interact to initiate and drive disease progression. In this review, we discuss the current understanding of PAH pathology and the role that genetic factors and environmental influences share in the development of vascular lesions and abnormal cell function. We also discuss how animal models can assist in elucidating gene function and the study of novel therapeutics, while at the same time addressing the limitations of the most commonly used rodent models. Novel experimental approaches based on application of next generation sequencing, bioinformatics and epigenetics research are also discussed as these are now being actively used to facilitate the discovery of novel gene mutations and mechanisms that regulate gene expression in PAH. Finally, we touch on recent discoveries concerning the role of inflammation and immunity in PAH pathobiology and how they are being targeted with immunomodulatory agents. We conclude that the field of PAH research is actively expanding and the major challenge in the coming years is to develop a unified theory that incorporates genetic and mechanistic data to address viable areas for disease modifying drugs that can target key processes that regulate the evolution of vascular pathology of PAH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Hunter DJ (2005) Gene-environment interactions in human diseases. Nat Rev Genet 6:287–298

    Article  CAS  PubMed  Google Scholar 

  2. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J (2009) Accf/aha 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 53:1573–1619

    Article  PubMed  Google Scholar 

  3. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK et al (1987) Primary pulmonary hypertension. A national prospective study. Ann Intern Med 107:216–223

    Article  CAS  PubMed  Google Scholar 

  4. Morrell NW (2006) Pulmonary hypertension due to bmpr2 mutation: a new paradigm for tissue remodeling? Proc Am Thorac Soc 3:680–686

    Article  CAS  PubMed  Google Scholar 

  5. Chin KM, Kim NH, Rubin LJ (2005) The right ventricle in pulmonary hypertension. Coron Artery Dis 16:13–18

    Article  PubMed  Google Scholar 

  6. Chin KM, Rubin LJ (2008) Pulmonary arterial hypertension. J Am Coll Cardiol 51:1527–1538

    Article  PubMed  Google Scholar 

  7. Rubin LJ (2006) Pulmonary arterial hypertension. Proc Am Thorac Soc 3:111–115

    Article  CAS  PubMed  Google Scholar 

  8. Tuder RM, Archer SL, Dorfmuller P, Erzurum SC, Guignabert C, Michelakis E, Rabinovitch M, Schermuly R, Stenmark KR, Morrell NW (2013) Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 62:D4–12

    Article  PubMed  PubMed Central  Google Scholar 

  9. Tuder RM (2014) How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease. Drug Discov Today 19:1257–1263

    Article  PubMed  Google Scholar 

  10. Rabinovitch M (2001) Pathobiology of pulmonary hypertension Extracellular matrix. Clin Chest Med 22:433–449 viii

    Article  CAS  PubMed  Google Scholar 

  11. Heath D, Edwards JE (1958) The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 18:533–547

    Article  CAS  PubMed  Google Scholar 

  12. Heath D, Helmholz HF Jr, Burchell HB, Dushane JW, Edwards JE (1958) Graded pulmonary vascular changes and hemodynamic findings in cases of atrial and ventricular septal defect and patent ductus arteriosus. Circulation 18:1155–1166

    Article  CAS  PubMed  Google Scholar 

  13. Rabinovitch M, Haworth SG, Vance Z, Vawter G, Castaneda AR, Nadas AS, Reid LM (1980) Early pulmonary vascular changes in congenital heart disease studied in biopsy tissue. Hum Pathol 11:499–509

    CAS  PubMed  Google Scholar 

  14. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM (2012) Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 186:261–272

    Article  PubMed  PubMed Central  Google Scholar 

  15. Stenmark KR, Fagan KA, Frid MG (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 99:675–691

    Article  CAS  PubMed  Google Scholar 

  16. Stenmark KR, Frid MG (1998) Smooth muscle cell heterogeneity: role of specific smooth muscle cell subpopulations in pulmonary vascular disease. Chest 114:82S–90S

    Article  CAS  PubMed  Google Scholar 

  17. Coflesky JT, Adler KB, Woodcock-Mitchell J, Mitchell J, Evans JN (1988) Proliferative changes in the pulmonary arterial wall during short-term hyperoxic injury to the lung. Am J Pathol 132:563–573

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Ivy DD, McMurtry IF, Colvin K, Imamura M, Oka M, Lee DS, Gebb S, Jones PL (2005) Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 111:2988–2996

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Montani D, Chaumais MC, Guignabert C, Gunther S, Girerd B, Jais X, Algalarrondo V, Price LC, Savale L, Sitbon O, Simonneau G, Humbert M (2014) Targeted therapies in pulmonary arterial hypertension. Pharmacol Ther 141:172–191

    Article  CAS  PubMed  Google Scholar 

  20. Boutet K, Montani D, Jais X, Yaici A, Sitbon O, Simonneau G, Humbert M (2008) Therapeutic advances in pulmonary arterial hypertension. Ther Adv Respir Dis 2:249–265

    Article  CAS  PubMed  Google Scholar 

  21. Zaidi SH, You XM, Ciura S, Husain M, Rabinovitch M (2002) Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 105:516–521

    Article  CAS  PubMed  Google Scholar 

  22. Nickel NP, Spiekerkoetter E, Gu M, Li CG, Li H, Kaschwich M, Diebold I, Hennigs JK, Kim KY, Miyagawa K, Wang L, Cao A, Sa S, Jiang X, Stockstill RW, Nicolls MR, Zamanian RT, Bland RD, Rabinovitch M (2015) Elafin reverses pulmonary hypertension via caveolin-1-dependent bone morphogenetic protein signaling. Am J Respir Crit Care Med 191:1273–1286

    Article  CAS  PubMed  Google Scholar 

  23. Rabinovitch M (1999) Eve and beyond, retro and prospective insights. Am J Physiol 277:L5–12

    CAS  PubMed  Google Scholar 

  24. Rabinovitch M (2012) Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 122:4306–4313

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Tuder RM, Cool CD, Yeager M, Taraseviciene-Stewart L, Bull TM, Voelkel NF (2001) The pathobiology of pulmonary hypertension. Endothelium. Clin Chest Med 22:405–418

    Article  CAS  PubMed  Google Scholar 

  26. Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Yeager ME, Golpon HA, Voelkel NF, Tuder RM (2002) Microsatellite mutational analysis of endothelial cells within plexiform lesions from patients with familial, pediatric, and sporadic pulmonary hypertension. Chest 121:61S

    Article  PubMed  Google Scholar 

  28. Tuder RM, Voelkel NF (2002) Angiogenesis and pulmonary hypertension: a unique process in a unique disease. Antioxid Redox Signal 4:833–843

    Article  CAS  PubMed  Google Scholar 

  29. Lee SD, Shroyer KR, Markham NE, Cool CD, Voelkel NF, Tuder RM (1998) Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101:927–934

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF (2008) The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 178:558–564

    Article  PubMed  PubMed Central  Google Scholar 

  31. van Dijk CG, Nieuweboer FE, Pei JY, Xu YJ, Burgisser P, van Mulligen E, El Azzouzi H, Duncker DJ, Verhaar MC, Cheng C (2015) The complex mural cell: pericyte function in health and disease. Int J Cardiol 190:75–89

    Article  PubMed  Google Scholar 

  32. Birbrair A, Zhang T, Wang ZM, Messi ML, Mintz A, Delbono O (2014) Pericytes: multitasking cells in the regeneration of injured, diseased, and aged skeletal muscle. Front Aging Neurosci 6:245

    Article  PubMed  PubMed Central  Google Scholar 

  33. Dore-Duffy P (2014) Pericytes and adaptive angioplasticity: the role of tumor necrosis factor-like weak inducer of apoptosis (tweak). Methods Mol Biol 1135:35–52

    Article  CAS  PubMed  Google Scholar 

  34. El-Bizri N, Wang L, Merklinger SL, Guignabert C, Desai T, Urashima T, Sheikh AY, Knutsen RH, Mecham RP, Mishina Y, Rabinovitch M (2008) Smooth muscle protein 22alpha-mediated patchy deletion of bmpr1a impairs cardiac contractility but protects against pulmonary vascular remodeling. Circ Res 102:380–388

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Ricard N, Tu L, Le Hiress M, Huertas A, Phan C, Thuillet R, Sattler C, Fadel E, Seferian A, Montani D, Dorfmuller P, Humbert M, Guignabert C (2014) Increased pericyte coverage mediated by endothelial-derived fibroblast growth factor-2 and interleukin-6 is a source of smooth muscle-like cells in pulmonary hypertension. Circulation 129:1586–1597

    Article  CAS  PubMed  Google Scholar 

  36. Yuan K, Orcholski ME, Panaroni C, Shuffle EM, Huang NF, Jiang X, Tian W, Vladar EK, Wang L, Nicolls MR, Wu JY, de Jesus Perez VA (2015) Activation of the wnt/planar cell polarity pathway is required for pericyte recruitment during pulmonary angiogenesis. Am J Pathol 185:69–84

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Durmowicz AG, Stenmark KR (1999) Mechanisms of structural remodeling in chronic pulmonary hypertension. Pediatr Rev 20:e91–e102

    CAS  PubMed  Google Scholar 

  38. Stenmark KR, Frid MG, Yeager M, Li M, Riddle S, McKinsey T, El Kasmi KC (2012) Targeting the adventitial microenvironment in pulmonary hypertension: a potential approach to therapy that considers epigenetic change. Pulm Circ 2:3–14

    Article  PubMed  PubMed Central  Google Scholar 

  39. Wang Z, Chesler NC (2011) Pulmonary vascular wall stiffness: an important contributor to the increased right ventricular afterload with pulmonary hypertension. Pulm Circ 1:212–223

    Article  PubMed  PubMed Central  Google Scholar 

  40. Rabinovitch M, Guignabert C, Humbert M, Nicolls MR (2014) Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res 115:165–175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, Hodge SE, Knowles JA (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67:737–744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, Thomson JR, 3rd Phillips JA, Loyd JE, Nichols WC, Trembath RC (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet 26:81–84

    Article  CAS  Google Scholar 

  43. Machado RD, Pauciulo MW, Thomson JR, Lane KB, Morgan NV, Wheeler L, Phillips JA 3rd, Newman J, Williams D, Galie N, Manes A, McNeil K, Yacoub M, Mikhail G, Rogers P, Corris P, Humbert M, Donnai D, Martensson G, Tranebjaerg L, Loyd JE, Trembath RC, Nichols WC (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92–102

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 37:741–745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Alastalo TP, Li M, Perez Vde J, Pham D, Sawada H, Wang JK, Koskenvuo M, Wang L, Freeman BA, Chang HY, Rabinovitch M (2011) Disruption of PPAR gamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial ec survival. J Clin Invest 121:3735–3746

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. de Jesus Perez VA, de Alastalo TP, Wu JC, Axelrod JD, Cooke JP, Amieva M, Rabinovitch M (2009) Bone morphogenetic protein 2 induces pulmonary angiogenesis via Wnt-beta-catenin and Wnt-Rhoa-Rac1 pathways. J Cell Biol 184:83–99

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  47. Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, El-Bizri N, Sawada H, Haghighat R, Chan R, Haghighat L, de Jesus Perez V, Wang L, Reddy S, Zhao M, Bernstein D, Solow-Cordero DE, Beachy PA, Wandless TJ, Ten Dijke P, Rabinovitch M (2013) Fk506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 123:3600–3613

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Girerd B, Montani D, Coulet F, Sztrymf B, Yaici A, Jais X, Tregouet D, Reis A, Drouin-Garraud V, Fraisse A, Sitbon O, O’Callaghan DS, Simonneau G, Soubrier F, Humbert M (2010) Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med 181:851–861

    Article  CAS  PubMed  Google Scholar 

  49. Sankelo M, Flanagan JA, Machado R, Harrison R, Rudarakanchana N, Morrell N, Dixon M, Halme M, Puolijoki H, Kere J, Elomaa O, Kupari M, Raisanen-Sokolowski A, Trembath RC, Laitinen T (2005) BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension. Hum Mutat 26:119–124

    Article  CAS  PubMed  Google Scholar 

  50. Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, Montani D, Souza R, Simonneau G, Soubrier F, Humbert M (2008) Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 177:1377–1383

    Article  CAS  PubMed  Google Scholar 

  51. Best DH, Austin ED, Chung WK, Elliott CG (2014) Genetics of pulmonary hypertension. Curr Opin Cardiol 29:520–527

    Article  PubMed  Google Scholar 

  52. Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA (2013) Correction of nonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 49:403–409

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Ryan JJ (2013) Chloroquine in pulmonary arterial hypertension: a new role for an old drug? Circ Cardiovasc Genet 6:310–311

    Article  PubMed  Google Scholar 

  54. Yang J, Li X, Al-Lamki RS, Wu C, Weiss A, Berk J, Schermuly RT, Morrell NW (2013) Sildenafil potentiates bone morphogenetic protein signaling in pulmonary arterial smooth muscle cells and in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 33:34–42

    Article  PubMed  CAS  Google Scholar 

  55. Drake KM, Zygmunt D, Mavrakis L, Harbor P, Wang L, Comhair SA, Erzurum SC, Aldred MA (2011) Altered microRNA processing in heritable pulmonary arterial hypertension: an important role for SMAD-8. Am J Respir Crit Care Med 184:1400–1408

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Nasim MT, Ogo T, Ahmed M, Randall R, Chowdhury HM, Snape KM, Bradshaw TY, Southgate L, Lee GJ, Jackson I, Lord GM, Gibbs JS, Wilkins MR, Ohta-Ogo K, Nakamura K, Girerd B, Coulet F, Soubrier F, Humbert M, Morrell NW, Trembath RC, Machado RD (2011) Molecular genetic characterization of SMAD signaling molecules in pulmonary arterial hypertension. Hum Mutat 32:1385–1389

    Article  CAS  PubMed  Google Scholar 

  57. Lenato GM, Guanti G (2006) Hereditary haemorrhagic telangiectasia (HHT): genetic and molecular aspects. Curr Pharm Des 12:1173–1193

    Article  CAS  PubMed  Google Scholar 

  58. Newman JH, Trembath RC, Morse JA, Grunig E, Loyd JE, Adnot S, Coccolo F, Ventura C, Phillips JA 3rd, Knowles JA, Janssen B, Eickelberg O, Eddahibi S, Herve P, Nichols WC, Elliott G (2004) Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43:33S–39S

    Article  CAS  PubMed  Google Scholar 

  59. Pousada G, Baloira A, Vilarino C, Cifrian JM, Valverde D (2014) Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic parameters in patients with pulmonary arterial hypertension. PLoS One 9:e100261

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. de Jesus Perez VA, Yuan K, Lyuksyutova MA, Dewey F, Orcholski ME, Shuffle EM, Mathur M, Jr. Yancy L, Rojas V, Li CG, Cao A, Alastalo TP, Khazeni N, Cimprich KA, Butte AJ, Ashley E, Zamanian RT (2014) Whole-exome sequencing reveals TopBP1 as a novel gene in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 189:1260–1272

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Ma L, Roman-Campos D, Austin ED, Eyries M, Sampson KS, Soubrier F, Germain M, Tregouet DA, Borczuk A, Rosenzweig EB, Girerd B, Montani D, Humbert M, Loyd JE, Kass RS, Chung WK (2013) A novel channelopathy in pulmonary arterial hypertension. N Engl J Med 369:351–361

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Austin ED, Ma L, LeDuc C, Berman Rosenzweig E, Borczuk A, Phillips JA 3rd, Palomero T, Sumazin P, Kim HR, Talati MH, West J, Loyd JE, Chung WK (2012) Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 5:336–343

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Austin ED, Cogan JD, West JD, Hedges LK, Hamid R, Dawson EP, Wheeler LA, Parl FF, Loyd JE, Phillips JA 3rd (2009) Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur Respir J 34:1093–1099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. West J, Cogan J, Geraci M, Robinson L, Newman J, Phillips JA, Lane K, Meyrick B, Loyd J (2008) Gene expression in BMPR2 mutation carriers with and without evidence of pulmonary arterial hypertension suggests pathways relevant to disease penetrance. BMC Med Genomics 1:45

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  65. Frump AL, Goss KN, Vayl A, Albrecht M, Fisher A, Tursunova R, Fierst J, Whitson J, Cucci AR, Brown MB, Lahm T (2015) Estradiol improves right ventricular function in rats with severe angioproliferative pulmonary hypertension: effects of endogenous and exogenous sex hormones. Am J Physiol Lung Cell Mol Physiol 308:L873–L890

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  66. Lahm T, Crisostomo PR, Markel TA, Wang M, Weil BR, Novotny NM, Meldrum DR (2008) The effects of estrogen on pulmonary artery vasoreactivity and hypoxic pulmonary vasoconstriction: potential new clinical implications for an old hormone. Crit Care Med 36:2174–2183

    Article  CAS  PubMed  Google Scholar 

  67. Burg ED, Remillard CV, Yuan JX (2008) Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: pharmacotherapeutic implications. Br J Pharmacol 153(Suppl 1):S99–S111

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Fantozzi I, Platoshyn O, Wong AH, Zhang S, Remillard CV, Furtado MR, Petrauskene OV, Yuan JX (2006) Bone morphogenetic protein-2 upregulates expression and function of voltage-gated k+ channels in human pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 291:L993–1004

    Article  CAS  PubMed  Google Scholar 

  69. Ko EA, Burg ED, Platoshyn O, Msefya J, Firth AL, Yuan JX (2007) Functional characterization of voltage-gated k+ channels in mouse pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 293:C928–C937

    Article  CAS  PubMed  Google Scholar 

  70. Mandegar M, Remillard CV, Yuan JX (2002) Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 45:81–114

    Article  CAS  PubMed  Google Scholar 

  71. Mandegar M, Yuan JX (2002) Role of k + channels in pulmonary hypertension. Vasc Pharmacol 38:25–33

    Article  CAS  Google Scholar 

  72. Olschewski A, Li Y, Tang B, Hanze J, Eul B, Bohle RM, Wilhelm J, Morty RE, Brau ME, Weir EK, Kwapiszewska G, Klepetko W, Seeger W, Olschewski H (2006) Impact of task-1 in human pulmonary artery smooth muscle cells. Circ Res 98:1072–1080

    Article  CAS  PubMed  Google Scholar 

  73. Gurney A, Manoury B (2009) Two-pore potassium channels in the cardiovascular system. Eur Biophys J 38:305–318

    Article  CAS  PubMed  Google Scholar 

  74. Tang B, Li Y, Nagaraj C, Morty RE, Gabor S, Stacher E, Voswinckel R, Weissmann N, Leithner K, Olschewski H, Olschewski A (2009) Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 41:476–483

    Article  CAS  PubMed  Google Scholar 

  75. Manoury B, Lamalle C, Oliveira R, Reid J, Gurney AM (2011) Contractile and electrophysiological properties of pulmonary artery smooth muscle are not altered in TASK-1 knockout mice. J Physiol 589:3231–3246

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Fernandez RA, Wan J, Song S, Smith KA, Gu Y, Tauseef M, Tang H, Makino A, Mehta D, Yuan JX (2015) Upregulated expression of STIM2, TRPC6, and Orai2 contributes to the transition of pulmonary arterial smooth muscle cells from a contractile to proliferative phenotype. Am J Physiol Cell Physiol 308:C581–C593

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Smith KA, Voiriot G, Tang H, Fraidenburg DR, Song S, Yamamura H, Yamamura A, Guo Q, Wan J, Pohl NM, Tauseef M, Bodmer R, Ocorr K, Thistlethwaite PA, Haddad GG, Powell FL, Makino A, Mehta D, Yuan JX (2015) Notch activation of ca signaling mediates hypoxic pulmonary vasoconstriction and pulmonary hypertension. Am J Respir Cell Mol Biol 53(3):355–367

    Article  CAS  PubMed  Google Scholar 

  78. Liu XR, Zhang MF, Yang N, Liu Q, Wang RX, Cao YN, Yang XR, Sham JS, Lin MJ (2012) Enhanced store-operated ca(2)+ entry and trpc channel expression in pulmonary arteries of monocrotaline-induced pulmonary hypertensive rats. Am J Physiol Cell Physiol 302:C77–C87

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Wang C, Li JF, Zhao L, Liu J, Wan J, Wang YX, Wang J, Wang C (2009) Inhibition of SOC/Ca2+/Nfat pathway is involved in the anti-proliferative effect of sildenafil on pulmonary artery smooth muscle cells. Respir Res 10:123

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  80. Xu L, Chen Y, Yang K, Wang Y, Tian L, Zhang J, Wang EW, Sun D, Lu W, Wang J (2014) Chronic hypoxia increases TRPC6 expression and basal intracellular ca2+ concentration in rat distal pulmonary venous smooth muscle. PLoS One 9:e112007

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  81. Leblanc N, Forrest AS, Ayon RJ, Wiwchar M, Angermann JE, Pritchard HA, Singer CA, Valencik ML, Britton F, Greenwood IA (2015) Molecular and functional significance of ca(2+)-activated cl(−) channels in pulmonary arterial smooth muscle. Pulm Circ 5:244–268

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Zhu S, White RE, Barman SA (2008) Role of phosphodiesterases in modulation of BKCa channels in hypertensive pulmonary arterial smooth muscle. Ther Adv Respir Dis 2:119–127

    Article  PubMed  PubMed Central  Google Scholar 

  83. Barman SA, Zhu S, Han G, White RE (2003) Camp activates bkca channels in pulmonary arterial smooth muscle via cgmp-dependent protein kinase. Am J Physiol Lung Cell Mol Physiol. 284:L1004–L1011

    Article  CAS  PubMed  Google Scholar 

  84. Dai ZK, Liu YW, Hsu JH, Yeh JL, Chen IJ, Wu JR, Wu BN (2015) The xanthine derivative KMUP-1 attenuates serotonin-induced vasoconstriction and k(+)-channel inhibitory activity via the PKC pathway in pulmonary arteries. Int J Biol Sci 11:633–642

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Dubuis E, Potier M, Wang R, Vandier C (2005) Continuous inhalation of carbon monoxide attenuates hypoxic pulmonary hypertension development presumably through activation of BKCA channels. Cardiovasc Res 65:751–761

    Article  CAS  PubMed  Google Scholar 

  86. Gai XY, Wei YH, Zhang W, Wuren TN, Wang YP, Li ZQ, Liu S, Ma L, Lu DX, Zhou Y, Ge RL (2015) Echinacoside induces rat pulmonary artery vasorelaxation by opening the NO-cGMP-PKG-BKCa channels and reducing intracellular ca2+ levels. Acta Pharmacol Sin 36:587–596

    Article  CAS  PubMed  Google Scholar 

  87. Bonnet S, Dumas-de-La-Roque E, Begueret H, Marthan R, Fayon M, Dos Santos P, Savineau JP, Baulieu EE (2003) Dehydroepiandrosterone (dhea) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 100:9488–9493

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Rehman J, Archer SL (2010) A proposed mitochondrial-metabolic mechanism for initiation and maintenance of pulmonary arterial hypertension in fawn-hooded rats: the warburg model of pulmonary arterial hypertension. Adv Exp Med Biol 661:171–185

    Article  CAS  PubMed  Google Scholar 

  89. Tuder RM, Davis LA, Graham BB (2012) Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension. Am J Respir Crit Care Med 185:260–266

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thebaud B, Bonnet S, Haromy A, Harry G, Moudgil R, McMurtry MS, Weir EK, Archer SL (2006) An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113:2630–2641

    Article  CAS  PubMed  Google Scholar 

  91. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, Krishnamachary B, Zhen L, Mao T, Richter A, Erzurum SC, Tuder RM (2010) Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 176:1130–1138

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED (2007) A mitochondria-k+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51

    Article  CAS  PubMed  Google Scholar 

  93. Dromparis P, Sutendra G, Michelakis ED (2010) The role of mitochondria in pulmonary vascular remodeling. J Mol Med 88:1003–1010

    Article  CAS  PubMed  Google Scholar 

  94. McMurtry MS, Archer SL, Altieri DC, Bonnet S, Haromy A, Harry G, Bonnet S, Puttagunta L, Michelakis ED (2005) Gene therapy targeting survivin selectively induces pulmonary vascular apoptosis and reverses pulmonary arterial hypertension. J Clin Investig 115:1479–1491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, Michelakis ED (2004) Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830–840

    Article  CAS  PubMed  Google Scholar 

  96. Dromparis P, Paulin R, Stenson TH, Haromy A, Sutendra G, Michelakis ED (2013) Attenuating endoplasmic reticulum stress as a novel therapeutic strategy in pulmonary hypertension. Circulation 127:115–125

    Article  CAS  PubMed  Google Scholar 

  97. Ryter SW, Nakahira K, Haspel JA, Choi AM (2012) Autophagy in pulmonary diseases. Annu Rev Physiol 74:377–401

    Article  CAS  PubMed  Google Scholar 

  98. Sutendra G, Dromparis P, Wright P, Bonnet S, Haromy A, Hao Z, McMurtry MS, Michalak M, Vance JE, Sessa WC, Michelakis ED (2011) The role of nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med 3:88ra55

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Long L, Yang X, Southwood M, Lu J, Marciniak SJ, Dunmore BJ, Morrell NW (2013) Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type ii receptor degradation. Circ Res 112:1159–1170

    Article  CAS  PubMed  Google Scholar 

  100. Lahm T, Petrache I (2012) LC3 as a potential therapeutic target in hypoxia-induced pulmonary hypertension. Autophagy 8:1146–1147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Lee SJ, Smith A, Guo L, Alastalo TP, Li M, Sawada H, Liu X, Chen ZH, Ifedigbo E, Jin Y, Feghali-Bostwick C, Ryter SW, Kim HP, Rabinovitch M, Choi AM (2011) Autophagic protein LC3B confers resistance against hypoxia-induced pulmonary hypertension. Am J Respir Crit Care Med 183:649–658

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Kumar RK, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R (2013) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 62:D34–D41

    Article  PubMed  Google Scholar 

  103. de Jesus Perez V, Kudelko K, Snook S, Zamanian RT (2011) Drugs and toxins-associated pulmonary arterial hypertension: lessons learned and challenges ahead. Int J Clin Pract Suppl (169):8–10

  104. Montani D, Seferian A, Savale L, Simonneau G, Humbert M (2013) Drug-induced pulmonary arterial hypertension: a recent outbreak. Eur Respir Rev 22:244–250

    Article  PubMed  Google Scholar 

  105. Gross SB (1999) Appetite suppressants and cardiac valvulopathy. Current clinical perspectives. Adv Nurse Pract 7:36–40

    CAS  PubMed  Google Scholar 

  106. Seiler KU, Wassermann O, Wensky H (1976) On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs; an experimental study in the isolated perfused rat lung, II. Fenfluramine, mazindol, mefenorex, phentermine and R 800. Clin. Exp Pharmacol Physiol. 3:323–330

    Article  CAS  PubMed  Google Scholar 

  107. Wang Y, Liu M, Wang HM, Bai Y, Zhang XH, Sun YX, Wang HL (2013) Involvement of serotonin mechanism in methamphetamine-induced chronic pulmonary toxicity in rats. Hum Exp Toxicol 32:736–746

    Article  PubMed  CAS  Google Scholar 

  108. Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock AJ, Harmar A, Bader M, MacLean MR (2008) Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation 117:2928–2937

    Article  CAS  PubMed  Google Scholar 

  109. Lawrie A, Spiekerkoetter E, Martinez EC, Ambartsumian N, Sheward WJ, MacLean MR, Harmar AJ, Schmidt AM, Lukanidin E, Rabinovitch M (2005) Interdependent serotonin transporter and receptor pathways regulate S100A4/Mts1, a gene associated with pulmonary vascular disease. Circ Res 97:227–235

    Article  CAS  PubMed  Google Scholar 

  110. Dempsie Y, Nilsen M, White K, Mair KM, Loughlin L, Ambartsumian N, Rabinovitch M, Maclean MR (2011) Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respir Res 12:159

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  111. Spiekerkoetter E, Alvira CM, Kim YM, Bruneau A, Pricola KL, Wang L, Ambartsumian N, Rabinovitch M (2008) Reactivation of gamma hv 68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am J Physiol Lung Cell Mol Physiol 294:L276–L289

    Article  CAS  PubMed  Google Scholar 

  112. Meloche J, Courchesne A, Barrier M, Carter S, Bisserier M, Paulin R, Lauzon-Joset JF, Breuils-Bonnet S, Tremblay E, Biardel S, Racine C, Courture C, Bonnet P, Majka SM, Deshaies Y, Picard F, Provencher S, Bonnet S (2013) Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2:e005157

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Schaiberger PH, Kennedy TC, Miller FC, Gal J, Petty TL (1993) Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine. Chest 104:614–616

    Article  CAS  PubMed  Google Scholar 

  114. Thompson CA (2008) Pulmonary arterial hypertension seen in methamphetamine abusers. Am J Health Syst Pharm 65:1109–1110

    Article  PubMed  Google Scholar 

  115. Perros F, Gunther S, Ranchoux B, Godinas L, Antigny F, Chaumais MC, Dorfmuller P, Hautefort A, Raymond N, Savale L, Jais X, Girerd B, Cottin V, Sitbon O, Simonneau G, Humbert M, Montani D (2015) Mitomycin-induced pulmonary veno-occlusive disease: evidence from human disease and animal models. Circulation 132:834–847

    Article  CAS  PubMed  Google Scholar 

  116. Ryan JJ, Marsboom G, Archer SL (2013) Rodent models of group 1 pulmonary hypertension. Handb Exp Pharmacol 218:105–149

    Article  CAS  PubMed  Google Scholar 

  117. Roth RA, Reindel JF (1991) Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv Exp Med Biol 283:477–487

    Article  CAS  PubMed  Google Scholar 

  118. Schultze AE, Roth RA (1998) Chronic pulmonary hypertension—the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev. 1:271–346

    Article  CAS  PubMed  Google Scholar 

  119. Wilson DW, Segall HJ, Pan LC, Lame MW, Estep JE, Morin D (1992) Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 22:307–325

    Article  CAS  PubMed  Google Scholar 

  120. Campbell AI, Kuliszewski MA, Stewart DJ (1999) Cell-based gene transfer to the pulmonary vasculature: endothelial nitric oxide synthase overexpression inhibits monocrotaline-induced pulmonary hypertension. Am J Respir Cell Mol Biol 21:567–575

    Article  CAS  PubMed  Google Scholar 

  121. Zhao YD, Courtman DW, Deng Y, Kugathasan L, Zhang Q, Stewart DJ (2005) Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96:442–450

    Article  CAS  PubMed  Google Scholar 

  122. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, Voelkel NF, Bogaard HJ (2012) The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol. 302:L363–L369

    Article  CAS  PubMed  Google Scholar 

  123. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD (1997) Pulmonary hemodynamics modify the rat pulmonary artery response to injury. A neointimal model of pulmonary hypertension. Am J Pathol 151:1019–1025

    CAS  PubMed  PubMed Central  Google Scholar 

  124. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C, Wood K, Parr JE, Boackle SA, Voelkel NF (2007) Absence of t cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 175:1280–1289

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  125. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M (2010) Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 121:2747–2754

    Article  PubMed  Google Scholar 

  126. Vitali SH, Hansmann G, Rose C, Fernandez-Gonzalez A, Scheid A, Mitsialis SA, Kourembanas S (2014) The sugen 5416/hypoxia mouse model of pulmonary hypertension revisited: long-term follow-up. Pulm Circ 4:619–629

    Article  PubMed  PubMed Central  Google Scholar 

  127. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD (2004) BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 287:L1241–L1247

    Article  CAS  PubMed  Google Scholar 

  128. Beppu H, Lei H, Bloch KD, Li E (2005) Generation of a floxed allele of the mouse BMP type II receptor gene. Genesis 41:133–137

    Article  CAS  PubMed  Google Scholar 

  129. West J, Harral J, Lane K, Deng Y, Ickes B, Crona D, Albu S, Stewart D, Fagan K (2008) Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. Am J Physiol Lung Cell Mol Physiol 295:L744–L755

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  130. Ranchoux B, Antigny F, Rucker-Martin C, Hautefort A, Pechoux C, Bogaard HJ, Dorfmuller P, Remy S, Lecerf F, Plante S, Chat S, Fadel E, Houssaini A, Anegon I, Adnot S, Simonneau G, Humbert M, Cohen-Kaminsky S, Perros F (2015) Endothelial-to-mesenchymal transition in pulmonary hypertension. Circulation 131:1006–1018

    Article  CAS  PubMed  Google Scholar 

  131. Yuan K, Orcholski M, Tian X, Liao X, de Jesus Perez VA (2013) Micrornas: promising therapeutic targets for the treatment of pulmonary arterial hypertension. Expert Opin Ther Targets 17:557–564

    Article  CAS  PubMed  Google Scholar 

  132. Bienertova-Vasku J, Novak J, Vasku A (2015) Micrornas in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. J Am Soc Hypertens 9:221–234

    Article  CAS  PubMed  Google Scholar 

  133. Sarkar J, Gou D, Turaka P, Viktorova E, Ramchandran R, Raj JU (2010) Microrna-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 299:L861–L871

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  134. Yang S, Banerjee S, Freitas A, Cui H, Xie N, Abraham E, Liu G (2012) miR-21 regulates chronic hypoxia-induced pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol 302:L521–L529

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  135. Bockmeyer CL, Maegel L, Janciauskiene S, Rische J, Lehmann U, Maus UA, Nickel N, Haverich A, Hoeper MM, Golpon HA, Kreipe H, Laenger F, Jonigk D (2012) Plexiform vasculopathy of severe pulmonary arterial hypertension and microrna expression. J Heart Lung Transplant 31:764–772

    Article  PubMed  Google Scholar 

  136. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, Waxman AB (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104:236–244, 228p following 244

  137. Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal BK, Ghofrani HA, Weissmann N, Grimminger F, Bonauer A, Seeger W, Zeiher AM, Dimmeler S, Schermuly RT (2012) Inhibition of microrna-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 185:409–419

    Article  CAS  PubMed  Google Scholar 

  138. Courboulin A, Paulin R, Giguere NJ, Saksouk N, Perreault T, Meloche J, Paquet ER, Biardel S, Provencher S, Cote J, Simard MJ, Bonnet S (2011) Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 208:535–548

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  139. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, Antigny F, Tremblay E, Breuils-Bonnet S, Perros F, Provencher S, Bonnet S (2015) miR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol 309:C363–C372

    Article  CAS  PubMed  Google Scholar 

  140. Deng L, Blanco FJ, Stevens H, Lu R, Caudrillier A, McBride M, McClure JD, Grant J, Thomas M, Frid M, Stenmark K, White K, Seto AG, Morrell NW, Bradshaw AC, MacLean MR, Baker AH (2015) MicroRNA-143 activation regulates smooth muscle and endothelial cell crosstalk in pulmonary arterial hypertension. Circ Res 117:870–883

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  141. Caruso P, Dempsie Y, Stevens HC, McDonald RA, Long L, Lu R, White K, Mair KM, McClure JD, Southwood M, Upton P, Xin M, van Rooij E, Olson EN, Morrell NW, MacLean MR, Baker AH (2012) A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 111:290–300

    Article  CAS  PubMed  Google Scholar 

  142. Bertero T, Cottrill K, Krauszman A, Lu Y, Annis S, Hale A, Bhat B, Waxman AB, Chau BN, Kuebler WM, Chan SY (2015) The microRNA-130/301 family controls vasoconstriction in pulmonary hypertension. J Biol Chem 290:2069–2085

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  143. Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R, Saggar R, Wallace WD, Ross DJ, Vargas SO, Graham BB, Kumar R, Black SM, Fratz S, Fineman JR, West JD, Haley KJ, Waxman AB, Chau BN, Cottrill KA, Chan SY (2014) Systems-level regulation of microrna networks by miR-130/301 promotes pulmonary hypertension. J Clin Invest 124:3514–3528

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. White K, Loscalzo J, Chan SY (2012) Holding our breath: the emerging and anticipated roles of microrna in pulmonary hypertension. Pulm Circ 2:278–290

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Kim GH, Ryan JJ, Marsboom G, Archer SL (2011) Epigenetic mechanisms of pulmonary hypertension. Pulm Circ 1:347–356

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR (2012) Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 126:455–467

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  147. Lan B, Hayama E, Kawaguchi N, Furutani Y, Nakanishi T (2015) Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension. PLoS One 10:e0117211

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  148. Bogaard HJ, Mizuno S, Hussaini AA, Toldo S, Abbate A, Kraskauskas D, Kasper M, Natarajan R, Voelkel NF (2011) Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med 183:1402–1410

    Article  CAS  PubMed  Google Scholar 

  149. Archer SL, Marsboom G, Kim GH, Zhang HJ, Toth PT, Svensson EC, Dyck JR, Gomberg-Maitland M, Thebaud B, Husain AN, Cipriani N, Rehman J (2010) Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121:2661–2671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  150. Wang Y, Kahaleh B (2013) Epigenetic repression of bone morphogenetic protein receptor II expression in scleroderma. J Cell Mol Med 17:1291–1299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  151. Aldred MA, Comhair SA, Varella-Garcia M, Asosingh K, Xu W, Noon GP, Thistlethwaite PA, Tuder RM, Erzurum SC, Geraci MW, Coldren CD (2010) Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 182:1153–1160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  152. Machado RD, James V, Southwood M, Harrison RE, Atkinson C, Stewart S, Morrell NW, Trembath RC, Aldred MA (2005) Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 111:607–613

    Article  CAS  PubMed  Google Scholar 

  153. Federici C, Drake KM, Rigelsky CM, McNelly LN, Meade SL, Comhair SA, Erzurum SC, Aldred MA (2015) Increased mutagen sensitivity and DNA damage in pulmonary arterial hypertension. Am J Respir Crit Care Med 192:219–228

    Article  CAS  PubMed  Google Scholar 

  154. Li M, Vattulainen S, Aho J, Orcholski M, Rojas V, Yuan K, Helenius M, Taimen P, Myllykangas S, De Jesus Perez V, Koskenvuo JW, Alastalo TP (2014) Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 50:1118–1128

    Article  PubMed  CAS  Google Scholar 

  155. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, Graydon C, Courboulin A, Breuils-Bonnet S, Tremblay E, Couture C, Michelakis ED, Provencher S, Bonnet S (2014) Role for DNA damage signaling in pulmonary arterial hypertension. Circulation 129:786–797

    Article  CAS  PubMed  Google Scholar 

  156. Dib H, Tamby MC, Bussone G, Regent A, Berezne A, Lafine C, Broussard C, Simonneau G, Guillevin L, Witko-Sarsat V, Humbert M, Mouthon L (2012) Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 39:1405–1414

    Article  CAS  PubMed  Google Scholar 

  157. Nicolls MR, Taraseviciene-Stewart L, Rai PR, Badesch DB, Voelkel NF (2005) Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 26:1110–1118

    Article  CAS  PubMed  Google Scholar 

  158. Hagen M, Fagan K, Steudel W, Carr M, Lane K, Rodman DM, West J (2007) Interaction of interleukin-6 and the BMP pathway in pulmonary smooth muscle. Am J Physiol Lung Cell Mol Physiol 292:L1473–L1479

    Article  CAS  PubMed  Google Scholar 

  159. Courboulin A, Tremblay VL, Barrier M, Meloche J, Jacob MH, Chapolard M, Bisserier M, Paulin R, Lambert C, Provencher S, Bonnet S (2011) Kruppel-like factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 12:128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  160. Savale L, Tu L, Rideau D, Izziki M, Maitre B, Adnot S, Eddahibi S (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10:6

    Article  PubMed  PubMed Central  Google Scholar 

  161. Golembeski SM, West J, Tada Y, Fagan KA (2005) Interleukin-6 causes mild pulmonary hypertension and augments hypoxia-induced pulmonary hypertension in mice. Chest 128:572S–573S

    Article  PubMed  Google Scholar 

  162. Good RB, Gilbane AJ, Trinder SL, Denton CP, Coghlan G, Abraham DJ, Holmes AM (2015) Endothelial to mesenchymal transition contributes to endothelial dysfunction in pulmonary arterial hypertension. Am J Pathol 185:1850–1858

    Article  CAS  PubMed  Google Scholar 

  163. Bonnet S, Rochefort G, Sutendra G, Archer SL, Haromy A, Webster L, Hashimoto K, Bonnet SN, Michelakis ED (2007) The nuclear factor of activated t cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci USA 104:11418–11423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Macian F (2005) Nfat proteins: key regulators of t-cell development and function. Nat Rev Immunol 5:472–484

    Article  CAS  PubMed  Google Scholar 

  165. Heissmeyer V, Macian F, Varma R, Im SH, Garcia-Cozar F, Horton HF, Byrne MC, Feske S, Venuprasad K, Gu H, Liu YC, Dustin ML, Rao A (2005) A molecular dissection of lymphocyte unresponsiveness induced by sustained calcium signalling. Novartis Found Symp 267:165–174 (discussion 174–169)

    Article  CAS  PubMed  Google Scholar 

  166. Thenappan T, Goel A, Marsboom G, Fang YH, Toth PT, Zhang HJ, Kajimoto H, Hong Z, Paul J, Wietholt C, Pogoriler J, Piao L, Rehman J, Archer SL (2011) A central role for cd68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion. Am J Respir Crit Care Med 183:1080–1091

    Article  PubMed  PubMed Central  Google Scholar 

  167. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR (2013) Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Science translational medicine. 5:200ra117

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  168. Kim YM, Haghighat L, Spiekerkoetter E, Sawada H, Alvira CM, Wang L, Acharya S, Rodriguez-Colon G, Orton A, Zhao M, Rabinovitch M (2011) Neutrophil elastase is produced by pulmonary artery smooth muscle cells and is linked to neointimal lesions. Am J Pathol 179:1560–1572

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  169. Rabinovitch M (1995) Elastase and cell matrix interactions in the pathobiology of vascular disease. Acta Paediatr Jpn 37:657–666

    Article  CAS  PubMed  Google Scholar 

  170. Rabinovitch M (1998) Elastase and the pathobiology of unexplained pulmonary hypertension. Chest 114:213S–224S

    Article  CAS  PubMed  Google Scholar 

  171. Kobayashi J, Wigle D, Childs T, Zhu L, Keeley FW, Rabinovitch M (1994) Serum-induced vascular smooth muscle cell elastolytic activity through tyrosine kinase intracellular signalling. J Cell Physiol 160:121–131

    Article  CAS  PubMed  Google Scholar 

  172. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112:423–431

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary and Critical Care Medicine, Stanford University Medical Center, 300 Pasteur Drive Grant S140B, Stanford, CA, 94305, USA

    Vinicio A. de Jesus Perez

Authors
  1. Vinicio A. de Jesus Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vinicio A. de Jesus Perez.

Ethics declarations

Conflict of interest

Dr. de Jesus Perez has no conflict of interest or financial ties to disclose.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de Jesus Perez, V.A. Molecular pathogenesis and current pathology of pulmonary hypertension. Heart Fail Rev 21, 239–257 (2016). https://doi.org/10.1007/s10741-015-9519-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-015-9519-2

Keywords

Search

Navigation